Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Expert Opinion / Cases · November 10, 2021

Fit Mid-Fifties Female Patient With Progressive Brain Metastasis, Previous Serious Toxicity on Ipi/Nivo

Written by
Viola Franke MD


Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Matthew Smith-Cohn

    Nov 13, 2021

    Could consider the alliance trial brain metastasis trial if there are candidate alterations on NGS:
    It is worth discussion with radiation oncology of another round of SRS depending on the number of lesions. If there is radiation necrosis, bevacizumab can be considered. 

  • Jul 20, 2024

    Pending Moderator approval.

Further Reading